In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....
Read More
In a nutshell The report recommends how to manage patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed to respond to 2nd generation tyrosine kinase inhibitors (TKIs). The authors suggested to consider patient-specific factors and personalize treatment for such patients. Some background TKIs deactivate cancerous enzymes which cause...
Read More
In a nutshell This study aimed to investigate second treatments in patients with chronic myeloid leukemia (CML) who had been initially treated with second-generation tyrosine kinase inhibitors (TKI). This study concluded that switching from second-generation TKIs in these patients was relatively uncommon. Some background...
Read More
In a nutshell This study aimed to investigate kidney function in patients with chronic-phase (CP) chronic myeloid leukemia (CML) before and after tyrosine kinase inhibitor (TKI) treatment. This study concluded that long-term TKI treatment leads to kidney side effects in these patients that may be irreversible after stopping...
Read MoreIn a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...
Read MoreIn a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...
Read MoreIn a nutshell This study aimed to investigate the influence of stomach acid suppressants on dasatinib treatment in patients with chronic-phase chronic myeloid leukemia. This study concluded that these drugs did not influence dasatinib treatment in this patient group. Some background...
Read MoreIn a nutshell The study evaluated the combined effects of imatinib (IM; Gleevec) and hydroxychloroquine (HCQ; Plaquenil) in patients with chronic-phase chronic myeloid leukemia (CP-CML) and residual leukemic stem cells. The authors found that this combination safely and moderately improved treatment outcomes in such patients compared to IM alone. Some...
Read MoreIn a nutshell The study tested whether the EUTOS long-term survival (ELTS) score is efficient to evaluate treatment response in patients with chronic myeloid leukemia (CML), treated with imatinib (Gleevec). The main finding was that ELTS could effectively predict treatment outcomes among such patients in the real world. Some background Initial...
Read MoreIn a nutshell This study aimed to investigate the long-term outcomes of dasatinib treatment for patients with chronic myeloid leukemia. This study concluded that dasatinib is safe and provides positive long-term outcomes for these patients. Some background Dasatinib (Sprycel) is a targeted therapy...
Read MoreIn a nutshell This study aimed to investigate if asciminib was effective in patients with chronic myeloid leukemia who had resistance or unacceptable side effects to other tyrosine kinase inhibitors. This study concluded that asciminib showed promise in these patients. Some background Asciminib is a...
Read MoreIn a nutshell This study aimed to investigate the occurrence of hematological (blood-related) side effects in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. This study concluded that bone marrow fibrosis at diagnosis was a predictor of hematological side effects from tyrosine...
Read More
